Shimazaki A - Search Results

1

Ishida N, Odani-Kawabata N, Shimazaki A, Hara H. Ishida N, et al. Among authors: shimazaki a. Cardiovasc Drug Rev. 2006 Spring;24(1):1-10. doi: 10.1111/j.1527-3466.2006.00001.x. Cardiovasc Drug Rev. 2006. PMID: 16939629 Review.

2

[Effects of ocular hypotensive agents on the circadian rhythm in intraocular pressure in rabbits as measured by telemetry].

Akaishi T, Shimazaki A, Matsugi T, Miyawaki N, Hara H, Kuwayama Y. Akaishi T, et al. Among authors: shimazaki a. Nippon Ganka Gakkai Zasshi. 2003 Sep;107(9):513-8. Nippon Ganka Gakkai Zasshi. 2003. PMID: 14531310 Japanese.

3

Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug.

Takagi Y, Nakajima T, Shimazaki A, Kageyama M, Matsugi T, Matsumura Y, Gabelt BT, Kaufman PL, Hara H. Takagi Y, et al. Among authors: shimazaki a. Exp Eye Res. 2004 Apr;78(4):767-76. doi: 10.1016/j.exer.2003.12.007. Exp Eye Res. 2004. PMID: 15037111

4

New ethacrynic acid derivatives as potent cytoskeletal modulators in trabecular meshwork cells.

Shimazaki A, Suhara H, Ichikawa M, Matsugi T, Konomi K, Takagi Y, Hara H, Rao PV, Epstein DL. Shimazaki A, et al. Biol Pharm Bull. 2004 Jun;27(6):846-50. doi: 10.1248/bpb.27.846. Biol Pharm Bull. 2004. PMID: 15187431 Free article.

5

Effects of the new ethacrynic acid derivative SA9000 on intraocular pressure in cats and monkeys.

Shimazaki A, Ichikawa M, Rao PV, Kirihara T, Konomi K, Epstein DL, Hara H. Shimazaki A, et al. Biol Pharm Bull. 2004 Jul;27(7):1019-24. doi: 10.1248/bpb.27.1019. Biol Pharm Bull. 2004. PMID: 15256733 Free article.

6

Continuous monitoring of circadian variations in intraocular pressure by telemetry system throughout a 12-week treatment with timolol maleate in rabbits.

Akaishi T, Ishida N, Shimazaki A, Hara H, Kuwayama Y. Akaishi T, et al. Among authors: shimazaki a. J Ocul Pharmacol Ther. 2005 Dec;21(6):436-44. doi: 10.1089/jop.2005.21.436. J Ocul Pharmacol Ther. 2005. PMID: 16386085

7

Intravitreal injection of endothelin-1 caused optic nerve damage following to ocular hypoperfusion in rabbits.

Sasaoka M, Taniguchi T, Shimazawa M, Ishida N, Shimazaki A, Hara H. Sasaoka M, et al. Among authors: shimazaki a. Exp Eye Res. 2006 Sep;83(3):629-37. doi: 10.1016/j.exer.2006.03.007. Epub 2006 May 4. Exp Eye Res. 2006. PMID: 16677631

8

Endothelin-1 impairs retrograde axonal transport and leads to axonal injury in rat optic nerve.

Taniguchi T, Shimazawa M, Sasaoka M, Shimazaki A, Hara H. Taniguchi T, et al. Among authors: shimazaki a. Curr Neurovasc Res. 2006 May;3(2):81-8. doi: 10.2174/156720206776875867. Curr Neurovasc Res. 2006. PMID: 16719791

9

[Basis of anti-glaucoma agents].

Shimazaki A. Shimazaki A. Nihon Yakurigaku Zasshi. 2006 Oct;128(4):250-4. doi: 10.1254/fpj.128.250. Nihon Yakurigaku Zasshi. 2006. PMID: 17038790 Review. Japanese. No abstract available.

10

OCT evaluation of neuroprotective effects of tafluprost on retinal injury after intravitreal injection of endothelin-1 in the rat eye.

Nagata A, Omachi K, Higashide T, Shirae S, Shimazaki A, Nakamura M, Ishida N, Sugiyama K. Nagata A, et al. Among authors: shimazaki a. Invest Ophthalmol Vis Sci. 2014 Feb 20;55(2):1040-7. doi: 10.1167/iovs.13-13056. Invest Ophthalmol Vis Sci. 2014. PMID: 24458152

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

108 results

Search Page

Filters